Avita Medical Targets “Progressive” 2026 Growth, Guides $80M-$85M Revenue After Headwind Year

Core Insights - The company aims for progressive revenue growth in 2026, targeting revenue between $80 million and $85 million after a challenging 2025 [3][4][5] Financial Performance - The gross margin for 2025 was reported at 82.1%, with a forecast of 83% to 85% for 2026, driven by expected growth in RECELL products [1][6][7] - Revenue for 2025 was $71.6 million, including $17.6 million in Q4, with a stable growth outlook of 12% to 19% for 2026 [2][3] Operational Strategy - The company has focused on disciplined execution in cash management, headcount, and forecasting to enhance predictability and performance in 2026 [4][5] - A new $60 million credit facility was established to reset revenue and cash covenants, allowing for improved financial flexibility [6][15][16] Product Focus - The company is prioritizing its three-product platform, which includes RECELL, RECELL GO, Cohealyx, and PermeaDerm, aiming to increase utilization and adoption [12][17] - The commercialization of vitiligo has been deprioritized due to uncertain reimbursement conditions, with a focus on core product adoption instead [6][17] Sales and Market Strategy - The sales force has been restructured to focus on 200 key accounts, including burn centers and trauma centers, to drive growth in existing relationships [11][12] - The company is navigating reimbursement challenges, with updates on Medicare rates expected to improve the sales environment [9][10]